Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population.
After coronary stenting, the risk of developing restenosis is from 20 to 35 %. The aim of the present study is to investigate the association of genetic variation in candidate genes in patients diagnosed with restenosis in the Kazakh population.



Four hundred fifty-nine patients were recruited to the study; 91 patients were also diagnosed with diabetes and were excluded from the sampling. DNA was extracted with the salting-out method. The patients were genotyped for 53 single-nucleotide polymorphisms. Genotyping was performed on the QuantStudio 12K Flex (Life Technologies). Differences in distribution of BMI score among different genotype groups were compared by analysis of variance (ANOVA). Also, statistical analysis was performed using R and PLINK v.1.07. Haplotype frequencies and LD measures were estimated by using the software Haploview 4.2.



A logistic regression analysis found a significant difference in restenosis rates for different genotypes. FGB (rs1800790) is significantly associated with restenosis after stenting (OR = 2.924, P = 2.3E-06, additive model) in the Kazakh population. CD14 (rs2569190) showed a significant association in the additive (OR = 0.08033, P = 2.11E-09) and dominant models (OR = 0.05359, P = 4.15E-11). NOS3 (rs1799983) was also highly associated with development of restenosis after stenting in additive (OR = 20.05, P = 2.74 E-12) and recessive models (OR = 22.24, P = 6.811E-10).



Our results indicate that FGB (rs1800790), CD14 (rs2569190), and NOS3 (rs1799983) SNPs could be genetic markers for development of restenosis in Kazakh population. Adjustment for potential confounder factor BMI gave almost the same results.
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan. lenazhol@gmail.com.
Elena V
EV
Zholdybayeva
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.
Yerkebulan A
YA
Talzhanov
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.
Akbota M
AM
Aitkulova
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.
Pavel V
PV
Tarlykov
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.
Gulmira N
GN
Kulmambetova
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.|Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Aisha N
AN
Iskakova
National Scientific Medical Research Center, 42 Abylai Khan Avenue, Astana, Kazakhstan.
Aliya U
AU
Dzholdasbekova
Karaganda State Medical University, 40, Gogol Street, Karaganda, Kazakhstan.
Olga A
OA
Visternichan
Karaganda State Medical University, 40, Gogol Street, Karaganda, Kazakhstan.
Dana Zh
DZh
Taizhanova
National Center for Biotechnology, 13/5, KorgalzhinskoeHighway, Astana, Kazakhstan.|School of Science and Technology, Nazarbayev University, 53 Kabanbay Batyr Ave, Astana, Kazakhstan.
Yerlan M
YM
Ramanculov
D000368:Aged; D016022:Case-Control Studies; D023903:Coronary Restenosis / Q000235:genetics* / Q000517:prevention & control; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics; D007623:Kazakhstan; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D020641:Polymorphism, Single Nucleotide; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics; D012307:Risk Factors
C544065:AGTR1 protein, human; C508609:IL10 protein, human; D044140:Receptor, Angiotensin, Type 1; D016753:Interleukin-10
Coronary heart disease; Genotyping; Restenosis; SNP